Edition:
India

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

44.99USD
17 Nov 2017
Change (% chg)

-- (--)
Prev Close
$44.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
539,261
52-wk High
$46.98
52-wk Low
$11.42

Latest Key Developments (Source: Significant Developments)

EMA recommends against approval after re-examination of Nektar's drug onzeald
Friday, 10 Nov 2017 

Nov 10 (Reuters) - EU Medicines Agency::EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN‍​.  Full Article

Nektar Therapeutics reports Q3 earnings per share $0.39
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Nektar Therapeutics ::Nektar Therapeutics reports financial results for the third quarter of 2017.Q3 earnings per share $0.39.Q3 revenue $152.9 million versus $36.3 million.Q3 revenue view $114.6 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.17 -- Thomson Reuters I/B/E/S.  Full Article

Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration
Tuesday, 27 Sep 2016 

Bristol-myers Squibb Co : Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214 . Says Bristol-Myers Squibb and Nektar will equally share costs of combined therapy trials . Myers Squibb co - an initial dose-escalation trial is underway with Opdivo and NKTR-214 . Nektar will maintain its global commercial rights to NKTR-214 .Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214.  Full Article

Nektar Therapeutics reports Q2 loss per share $0.36
Thursday, 4 Aug 2016 

Nektar Therapeutics : Nektar Therapeutics reports financial results for the second quarter of 2016 . Q2 revenue $32.8 million versus I/B/E/S view $30.5 million . Q2 loss per share $0.36 .Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Nektar says co may pay Daiichi $12.5 mln termination payment
Wednesday, 1 Jun 2016 

Nektar :In case of pre-conditional approval termination of deal, nektar would be obligated to pay daiichi a $12.5 million termination payment - sec filing.  Full Article

BRIEF-Nektar Therapeutics, Daiichi Sankyo Europe sign licensing deal for breast cancer drug
Wednesday, 1 Jun 2016 

Corrects to add dropped words in the second bullet.Nektar Therapeutics : Nektar Therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments . Nektar Therapeutics says also entitled to significant double-digit royalties on net sales in Europe . Plans to submit an MAA filing in June 2016 seeking conditional approval from EMA for use of Onzeald .Nektar Therapeutics and Daiichi Sankyo Europe GmbH sign European licensing agreement for Onzeald(TM) (Etirinotecan Pegol), an investigational drug candidate being developed to treat patients with advanced breast cancer and brain metastases.  Full Article

Nektar Therapeutics and Daiichi Sankyo Europe sign European licensing agreement for onzeald experimental treatment for breast cancer and brain metastases
Wednesday, 1 Jun 2016 

Nektar Therapeutics Says Also Entitled To Significant Double : Nektar therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments . Digit royalties on net sales in europe . Plans to submit an maa filing in june 2016 seeking conditional approval from ema for use of onzeald .Nektar therapeutics and daiichi sankyo europe gmbh sign european licensing agreement for onzeald(tm) (etirinotecan pegol), an investigational drug candidate being developed to treat patients with advanced breast cancer and brain metastases.  Full Article

BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN‍​ Source text (http://bit.ly/2zxBcXv) Further company coverage: